Cardiovascular risk in type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 1, Issue SUPPL. 2, 1999, Pages 24-36

  Standl, E ^a  

^a Klinikum Schwabing   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; CARDIOVASCULAR DISEASE; DIABETIC ANGIOPATHY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; HYPERTENSION; INCIDENCE; RISK FACTORS;

EID: 0002677578     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.1999.0010s2024.x     Document Type: Review

References (73)

1. Edelman SV. Type II diabetes mellitus. Advances in Internal Medicine, 1998: 43: 449-500.
2. Standl E, Schnell O, Balletshofer B, et al. Influence of diabetes mellitus on the heart and macrovascular mortality. Diabetologica, 1997: 40 (Suppl. 2): S125-S126.
3. Standl E. Overview of the management of Type 2 diabetes. Diabetes Metabolism Review, 1998: 14 (Suppl. 1): S13-S17.
4. Standl E, Balletshofer B, Dahl B, et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologica, 1996: 39: 1540-1545.
5. Haffner SM, Miettinen H. Insulin resistance implications for Type 2 diabetes mellitus and coronary heart disease. American Journal of Medicine, 1997: 103: 152-162.
6. Keil U, Liese AD, Hense HW, et al. Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality in southern Germany. Results for the MONICA Augsburg cohort study 1984-92. Monitoring trends and determinants of cardiovascular disease. European Heart Journal, 1998: 19: 1197-1207.
7. Kohner EM, Aldington SJ, Stratton IM, et al. United Kingdom Prospective Diabetes Study 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Archives of Opthalmology, 1998: 116: 297-303.
8. McMillan DE. Development of vascular complications in diabetes. Vascular Medicine, 1997: 2: 132-142.
9. Mattock MB, Jeffers BW, Estacio R, Schrier RW. Associations of hypertension and complications in non-insulin dependent diabetes mellitus. American Journal of Hypertension, 1997: 10: 152-161.
10. Fedele D, Comi G, Cucinotta D, et al. A multicenter study on the prevalence of diabetic neuropathy in Italy. Italian Diabetic Neuropathy Committee. Diabetes Care, 1997: 20: 836-843.
11. Hanssen KF. Blood glucose control and microvascular and macrovascular complications in diabetes. Diabetes, 1997: 46 (Suppl. 2): S101-S103.
12. Klein R, Klein BE, Moss SE. Relation of glycaemic control to diabetic microvascular complications in diabetes mellitus. Annals of Internal Medicine, 1996: 124 (1 Part 2): 90-96.
13. Laakso M, Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis, 1998: 137 (Suppl.): S65-S73.
14. Garber AJ. Vascular disease and lipids in diabetes. Medicine Clinical North America, 1998: 82: 931-948.
15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet, 1998: 352: 837-853.
16. Assman G, Cullen P, Schulte H. The Münster Heart Study (PROCAM). Results of follow-up at 8 years. European Heart Journal, 1998: 19 (Suppl. A): A2-A11.
17. Cullen P, von Eckardstein A, Assmann G. Diagnosis and management of new cardiovascular risk factors. European Heart Journal, 1998: 19 (Suppl. O): O13-O19.
18. Assman G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. European Heart Journal, 1998: 19 (Suppl. M): M8-M14.
19. Stamler J, Vaccaro O, Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Diabetes Care, 1993: 16: 434-444.
20. Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes and impaired glucose tolerance. Diabetes Review, 1997: 5: 294-315.
21. Turner RC, Millns H, Neil HAW, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). British Medical Journal, 1998: 316: 823-888.
22. Turner RC. The UK Prospective Diabetes Study. Diabetes Care, 1998: 21 (Suppl. 3): C35-C38.
23. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care, 1995: 18: 258-242.
24. Pyörälä K. Type 2 diabetic subjects without prior myocardial infarction are at the same risk of coronary events as non-diabetic subjects with prior myocardial infarction. European Heart Journal, 1999: 20: 473-475.
25. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinaemia as an independent risk factor for ischaemic heart disease. New England Journal of Medicine, 1996: 334: 952-957.
26. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia, 1996: 39: 1577-1583.
27. Baron AD. Postprandial hyperglycaemia and alpha-glucosidae inhibitors. Diabetes Research and Clinical Practice, 1998: 40 (Suppl.): S51-S55.
28. Haller. The clinical importance of postprandial glucose. Diabetes Research and Clinical Practice, 1998: 40 (Suppl.): S43-S49.
29. Laakso M. Hypertension and macrovascular disease -the killing fields of NIDDM. Diabetes Research and Clinical Practice, 1998: 40 (Suppl.): S27-S33.
30. Meigs JB, Singer DE, Sullivan LM, et al. Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): the NIDDM Patient Outcome Research Team. American Journal of Medicine, 1997: 102: 38-42.
31. Mehler PS, Jeffers BW, Estacio R, Schrier RW. Associations of hypertension and complications in non-insulin-dependent diabetes mellitus. American Journal of Hypertension, 1997: 10: 152-161.
32. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care, 1978: 2: 120-126.
33. Laakso M. Benefits of strict glucose and blood pressure control in Type 2 diabetes. Circulation, 1999: 99: 461-462.
34. Bretzel RG, Voight K, Schatz H. The United Kingdom Prospective Diabetes Study (UKPDS): implications for pharmacotherapy of Type 2 diabetes mellitus. Experimental and Clinical Endocrinology and Diabetes, 1998: 106: 367-372.
35. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes (UKPDS 38). British Medical Journal, 1998: 317: 703-713.
36. Assman G, Schulte H, Cullen P. New and classical risk factors: the Münster Heart Study (PROCAM). European Heart Journal, 1997: 29: 237-242.
37. American Diabetes Association Position Statement. Management of dyslipidaemia in adults with diabetes. Diabetes Care, 1998: 21 (Suppl. 1): S36-S39.
38. Wei M, Gaskill SP, Haffner SM, Stern MO. Effects of diabetes and level of glycemia on all cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care, 1998: 21: 1167-1172.
39. Gotto AM Jr. Triglyceride as a risk factor for coronary artery disease. American Journal of Cardiology, 1998: 82: 22Q-25Q.
40. Taskinen MR, Smith U. Lipid disorders in NIDDM: implications for treatment. Journal of Internal Medicine, 1998: 244: 361-370.
41. Pontirolli AE, Pacchioni M, Camisasca R, Lattanzio R. Markers of insulin resistance are associated with cardiovascular morbidity and predict overall mortality in long-standing non-insulin-dependent diabetes mellitus. Acta Diabetologica, 1998: 35: 52-56.
42. Shaper AG, Wannaethee SG, Walker M. Body weight implications for the prevention of coronary artery disease, stroke and diabetes mellitus in a cohort study of middle aged men. British Medical Journal, 1997: 314: 1311-1317.
43. Serrano Rios M. Relationship between obesity and the increased risk of major complications in non-insulin-dependent diabetes mellitus. European Journal of Clinical Investigation, 1998: 28 (Suppl. 2): 14-17.
44. Wilding J. Obesity treatment. British Medical Journal, 1997: 315: 997-1000.
45. American Diabetes Association Position Statement. Diabetes mellitus and exercise. Diabetes Care, 1998: 21 (Suppl. 1): S40-S44.
46. American Diabetes Association Position Statement. Nutrition recommendations and principles for people with diabetes mellitus and exercise. Diabetes Care, 1998: 21 (Suppl. 1): S32-S35.
47. Hansson L, Zanchetti A, Dahlöf B, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 1998: 351: 1755-1762.
48. Malmberg K, Rydén L, Efendic S, et al. Randomised trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myo-cardial infarction (DIGAMI study): effects on mortality at 1 year. Journal of the American College of Cardiology, 1995: 26: 57-65.
49. Task Force Report. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. European Heart Journal, 1998: 19: 1434-1503.
50. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary artery heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis, 1998: 140: 199-270.
51. Alberti KG, Gries FA, Jervell J, Krans HM. A desktop guide for the management of non-insulin-dependent diabetes mellitus (NIDDM): an update. European NIDDM Policy Group. Diabetic Medicine, 1994: 11: 899-909.
52. European Arterial Risk Policy Group. A strategy for arterial risk assessment and management in Type 2 (non-insulin-dependent) diabetes mellitus. European Arterial Risk Policy Group on behalf of the International Diabetes Federation European Region. Diabetic Medicine, 1997: 14: 611-621.
53. Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, Munera CL. Advantages of alpha-glucosidase inhibitors as monotherapy in elderly Type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism, 1998: 83: 1515-1522.
54. Segal P, Feig PU, Schernthaner G, et al. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care, 1997: 20: 687-691.
55. Wolffenbuttel BH, Graal MB. New treatments for patients with Type 2 diabetes mellitus. Postgraduate Medical Journal, 1996: 72: 657-662.
56. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet, 1998: 352: 854-865.
57. Pagano G, Marena S, Corgiat-Mansin L, et al. Comparison of miglitol and glibenclamide in diet-treated Type 2 diabetic patients. Diabetes and Metabolism, 1995: 21: 162-167.
58. Mitrakou A, Tountas N, Raptis AE, Bauer RJ, Schulz H, Raptis SA. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated Type 2 diabetes mellitus. Diabetic Medicine, 1998: 15: 657-660.
59. Bohannon NJ. Coronary artery disease and diabetes. Postgraduate Medicine, 1999: 105: 66-80.
60. Yudkin JS. Lipids, thrombosis and cardiovascular disease in diabetes. Proceedings of the Nutrition Society, 1997: 56 (1B): 273-280.
61. Savage PJ. Treatment of diabetes mellitus to reduce its chronic cardiovascular complications. Current Opinions in Cardiology, 1998: 13: 131-138.
62. Genest J Jr, Cohn JS. Clustering of cardiovascular risk factors: targeting high-risk individuals. American Journal of Cardiology, 1995: 13: 8A-20A.
63. Pyörälä K, Savolainen E, Lehtovirta E, Punsae S, Siltanen P. Glucose tolerance and coronary heart disease: Helsinki policemen study. Journal of Chronic Disease, 1979: 32: 729-745.
64. Wandell PE, Brorsson B, Aberg H. Quality of life in diabetic patients registered with primary health care services in Sweden. Scandinavian Journal of Primary Health Care, 1997: 15: 97-102.
65. Ward J, Lin M, Heron G, Lajoie V. Comprehensive audit of quality of care and quality of life for patients with Type 2 diabetes. Journal of Qualitative Clinical Practice, 1997: 17: 91-100.
66. Anderson RM, Funnell MM, Butler PM, Arnold MS, Fitzgerald JT, Feste CC. Patient empowerment. Results of a randomized controlled trial. Diabetes Care, 1995: 18: 943-949.
67. Solberg LI, Reger LA, Pearson TL, et al. Using continuous quality improvement to improve diabetes care in populations: the IDEAL model. Improving care for Diabetics through Empowerment Active collaboration Leadership. Joint Communications Journal of Qualitative Improvement, 1997: 23: 581-592.
68. Butler RN, Rubenstein AH, Gracia AM, Zweig SC. Type 2 diabetes: patient education and home blood glucose monitoring. 3. Geriatrics, 1998: 6: 63-67.
69. DiGregorio RV. Managing heart failure in diabetic patients. Pharmacist, 1998: June: 101-112.
70. Feher MD. Hypertension in Diabetes Mellitus, 2nd edn. Martin Dunitz, London, 1994.
71. Morris AD, Boyle DIR, MacMahon AD. ACE inhibitor use is associated with hospitalization for severe hypoglycaemia in patients with diabetes. DARTS/ MEMO Collaboration. Diabetes Care, 1997: 20: 1362-1367.
72. O'Byrne S, Feely J. Effects of drugs on glucose tolerance in non-insulin-dependent diabetes (Part II). Drugs, 1990: 40: 203-219.
73. Stanton AV. Calcium channel blockers. The jury is still out on whether they cause heart attacks and suicide. British Medical Journal, 1998: 316: 1471-1473.